-DOCSTART- -X- O
Renin -X- _ O
angiotensin -X- _ O
system -X- _ O
( -X- _ O
RAS -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
key -X- _ O
hormonal -X- _ O
system -X- _ O
which -X- _ O
regulates -X- _ O
the -X- _ O
cardiovascular -X- _ O
function -X- _ O
and -X- _ O
is -X- _ O
implicated -X- _ O
in -X- _ O
several -X- _ O
autoimmune -X- _ O
diseases. -X- _ O
With -X- _ O
the -X- _ O
discovery -X- _ O
of -X- _ O
the -X- _ O
angiotensin-converting -X- _ O
enzyme -X- _ O
2 -X- _ O
( -X- _ O
ACE2 -X- _ O
) -X- _ O
, -X- _ O
a -X- _ O
protective -X- _ O
axis -X- _ O
of -X- _ O
RAS -X- _ O
namely -X- _ O
ACE2 -X- _ O
/ -X- _ O
Ang- -X- _ O
( -X- _ O
1–7 -X- _ O
) -X- _ O
/ -X- _ O
Mas -X- _ O
that -X- _ O
counteracts -X- _ O
the -X- _ O
deleterious -X- _ O
ACE -X- _ O
/ -X- _ O
AngII -X- _ O
/ -X- _ O
AT1R -X- _ O
axis -X- _ O
has -X- _ O
been -X- _ O
established. -X- _ O
This -X- _ O
axis -X- _ O
is -X- _ O
emerging -X- _ O
as -X- _ O
a -X- _ O
novel -X- _ O
target -X- _ O
to -X- _ O
attenuate -X- _ O
ocular -X- _ O
inflammation. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
underlying -X- _ O
molecular -X- _ O
mechanisms -X- _ O
remain -X- _ O
unclear. -X- _ O
We -X- _ O
investigated -X- _ O
the -X- _ O
hypothesis -X- _ O
that -X- _ O
enhancing -X- _ O
the -X- _ O
activity -X- _ O
of -X- _ O
the -X- _ O
protective -X- _ O
axis -X- _ O
of -X- _ O
RAS -X- _ O
by -X- _ O
subretinal -X- _ B-Intervention
delivery -X- _ I-Intervention
of -X- _ I-Intervention
an -X- _ I-Intervention
AAV8 -X- _ I-Intervention
( -X- _ I-Intervention
Y733F -X- _ I-Intervention
) -X- _ I-Intervention
-ACE2 -X- _ I-Intervention
vector -X- _ I-Intervention
would -X- _ O
protect -X- _ O
against -X- _ O
the -X- _ O
ocular -X- _ O
inflammation -X- _ O
in -X- _ O
experimental -X- _ B-Patient
autoimmune -X- _ I-Patient
uveitis -X- _ I-Patient
( -X- _ I-Patient
EAU -X- _ I-Patient
) -X- _ I-Patient
mice -X- _ I-Patient
through -X- _ O
regulating -X- _ O
the -X- _ O
local -X- _ O
immune -X- _ O
responses. -X- _ O
Our -X- _ O
studies -X- _ O
demonstrated -X- _ O
that -X- _ O
increased -X- _ B-Outcome
ACE2 -X- _ I-Outcome
expression -X- _ I-Outcome
exerts -X- _ I-Outcome
protective -X- _ I-Outcome
effects -X- _ I-Outcome
on -X- _ I-Outcome
inflammation -X- _ I-Outcome
in -X- _ I-Outcome
EAU -X- _ I-Outcome
mouse -X- _ I-Outcome
by -X- _ I-Outcome
modulating -X- _ I-Outcome
ocular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
the -X- _ I-Outcome
differentiation -X- _ I-Outcome
of -X- _ I-Outcome
Th1 -X- _ I-Outcome
/ -X- _ I-Outcome
Th17 -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
polarization -X- _ I-Outcome
of -X- _ I-Outcome
M1 -X- _ I-Outcome
/ -X- _ I-Outcome
M2 -X- _ I-Outcome
macrophages -X- _ I-Outcome
; -X- _ I-Outcome
whereas -X- _ I-Outcome
the -X- _ I-Outcome
systemic -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
appeared -X- _ I-Outcome
not -X- _ I-Outcome
affected. -X- _ I-Outcome
These -X- _ I-Outcome
effects -X- _ I-Outcome
were -X- _ I-Outcome
mediated -X- _ I-Outcome
by -X- _ I-Outcome
activating -X- _ I-Outcome
the -X- _ I-Outcome
Ang- -X- _ I-Outcome
( -X- _ I-Outcome
1–7 -X- _ I-Outcome
) -X- _ I-Outcome
/ -X- _ I-Outcome
Mas -X- _ I-Outcome
and -X- _ I-Outcome
inhibiting -X- _ I-Outcome
the -X- _ I-Outcome
MAPK -X- _ I-Outcome
, -X- _ I-Outcome
NF-κB -X- _ I-Outcome
and -X- _ I-Outcome
STAT3 -X- _ I-Outcome
signaling -X- _ I-Outcome
pathways. -X- _ I-Outcome
This -X- _ I-Outcome
proof-of-concept -X- _ I-Outcome
study -X- _ I-Outcome
suggests -X- _ I-Outcome
that -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
ocular -X- _ I-Outcome
ACE2 -X- _ I-Outcome
/ -X- _ I-Outcome
Ang- -X- _ I-Outcome
( -X- _ I-Outcome
1–7 -X- _ I-Outcome
) -X- _ I-Outcome
/ -X- _ I-Outcome
Mas -X- _ I-Outcome
axis -X- _ I-Outcome
with -X- _ I-Outcome
AAV -X- _ I-Outcome
gene -X- _ I-Outcome
transfer -X- _ I-Outcome
modulates -X- _ I-Outcome
local -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
, -X- _ I-Outcome
long-lasting -X- _ I-Outcome
therapeutic -X- _ I-Outcome
strategy -X- _ I-Outcome
for -X- _ I-Outcome
refractory -X- _ I-Outcome
and -X- _ I-Outcome
recurrent -X- _ I-Outcome
uveitis -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
other -X- _ I-Outcome
inflammatory -X- _ I-Outcome
eye -X- _ I-Outcome
diseases -X- _ I-Outcome
. -X- _ O

